Biodexa Pharmaceuticals Implements ADR Ratio Change

Biodexa Pharmaceuticals ( (BDRX) ) just unveiled an update.

On July 31, 2025, Biodexa Pharmaceuticals PLC announced the effective change in the ratio of its American Depositary Receipts (ADR) from one ADR representing ten thousand ordinary shares to one ADR representing one hundred thousand ordinary shares. This change, which acts as a one-for-ten reverse ADR split, was automatically implemented, with JPMorgan Chase Bank, N.A. handling the exchange. The total number of issued ordinary shares remains unchanged, but the number of ADRs outstanding is now 619,523. This adjustment is expected to impact the company’s market positioning by potentially enhancing the attractiveness of its ADRs to investors.

The most recent analyst rating on (BDRX) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Biodexa Pharmaceuticals stock, see the BDRX Stock Forecast page.

Spark’s Take on BDRX Stock

According to Spark, TipRanks’ AI Analyst, BDRX is a Neutral.

Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.

To see Spark’s full report on BDRX stock, click here.

More about Biodexa Pharmaceuticals

Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for the treatment of diseases with unmet medical needs.

Average Trading Volume: 2,601,077

Technical Sentiment Signal: Sell

Current Market Cap: $575.1K

For a thorough assessment of BDRX stock, go to TipRanks’ Stock Analysis page.